{
    "clinical_study": {
        "@rank": "102674", 
        "arm_group": [
            {
                "arm_group_label": "Radiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Systemic Chemotherapy Combined with Loco-regional Radiotherapy"
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemotherapy alone without Loco-regional Radiotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized parallel control trial to evaluate whether radical loco-regional\n      Radiotherapy can prolong survival time of initial untreated metastatic nasopharyngeal\n      carcinoma."
        }, 
        "brief_title": "Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma", 
        "completion_date": {
            "#text": "December 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patients with initial untreated metastatic nasopharyngeal carcinoma\n\n          -  Histologic diagnosis of nasopharyngeal carcinoma\n\n          -  T1-4N0-3M1,IVC(according to the 7th AJCC edition)\n\n          -  Aged between 18 and 65 years\n\n          -  KPS\u226570\n\n          -  The therapeutic effect evaluation is CR or PR accomplished three course of cisplatin\n             and 5-Fu\n\n          -  Voluntary to participate and sign informed consent document\n\n        Exclusion Criteria:\n\n          -  The patients sufferred from serious neurologic disease\n\n          -  Clinically significant cardiac, heart function less than or equal to 3 level\n\n          -  Clinically significant respiratory disease,lung function less than or equal to 3\n             level\n\n          -  Blood routine examination: WBC\uff1c3\u00d7109/L, Hemoglobin\uff1c90g/L, platelet count\uff1c75\u00d7109/L\n\n          -  Abnormal liver function: total bilirubin or ALT or AST\uff1e2\u00d7ULN\n\n          -  Abnormal renal function:serum creatinine\uff1e1.5\u00d7ULN\n\n          -  Pregnant or lactating women\n\n          -  The therapeutic effect evaluation is SD or PD accomplished three course of cisplatin\n             and 5-Fu"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "204", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111460", 
            "org_study_id": "SYSUCC5010"
        }, 
        "intervention": {
            "arm_group_label": [
                "Radiotherapy", 
                "Chemotherapy"
            ], 
            "description": "with or without Loco-regional Radiotherapy", 
            "intervention_name": "Loco-regional Radiotherapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Initially", 
            "Untreated", 
            "Distant metastatic"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "chenmy@sysucc.org.cn", 
                "last_name": "Ming y Chen, MD,PhD", 
                "phone": "86-20-8734-2422"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicentre Randomization Clinic Trial of Systemic Chemotherapy Combined With Loco-regional Radiotherapy vs. Chemotherapy Alone for Initially Untreated Distant Metastatic Nasopharyngeal Carcinoma With Chemosensitivity", 
        "overall_contact": {
            "email": "zouxiong@sysucc.org.cn", 
            "last_name": "Xiong Zou, MD", 
            "phone": "86-20-8734-2422"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Ming y Chen, MD,Phd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progress-free survival is calculated from the date of randomization to the date of the first progress at any site.", 
            "measure": "Progress-free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111460"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Ming-Yuan Chen", 
            "investigator_title": "associate professor & associate chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Administration and Monitoring Patients will be evaluated in the clinic and eligibility and informed consent obtained. Patients will be monitored for clinical toxicity by standard NIH criteria. QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) and EORTC QLQ Head and Neck. A time period of 4 weeks will constitute the time for clinical safety monitoring.", 
                "measure": "Determine the toxic effects, both quantitatively and qualitatively, and quality of life (QoL) of these regimens in these patients.", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the chemoradiotherapy treatment. Complete response defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.", 
                "measure": "Complete Response (CR)", 
                "safety_issue": "No", 
                "time_frame": "after the completion of the chemoradiotherapy treatment (up to 9 weeks)"
            }, 
            {
                "description": "The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.", 
                "measure": "Overall Survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.", 
                "measure": "Locoregional Relapse-Free Survival(LRRFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.", 
                "measure": "Distant Metastasis-Free Survival (DMFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The determination of cost, including direct cost drug fees, inspection fees, expenses and nursing cost; cost-effectiveness analysis, such as cost-effectiveness ratio (ratio of the direct cost and short - and long-term curative effect) and incremental cost-effectiveness ratio (i.e., increasing costs and increase short or long-term efficacy ratio).", 
                "measure": "Cost-effectiveness analysis", 
                "safety_issue": "No", 
                "time_frame": "completion of chemoradiotherapy  (up to 9 weeks)"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "First Affiliated Hospital, Sun Yat-Sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangdong Provincial People's Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}